Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Payers Like Biosimilars, But Rebates Remain The Bottom Line (For Now)

The US launch of Pfizer's Inflectra has been an early case study for the US biosimilar market, and some biosimilar manufacturers and payers say market access challenges are worrying.

Scrip 100 Biosimilars Reimbursement

Getting To Grips With International Reference Pricing

International reference pricing has become something of a fixture as payers around the world grapple with rising healthcare costs. The landscape is becoming more complex as the practice spreads further into emerging markets, reference baskets get bigger, and calls for pricing transparency grow louder. Scrip examines some of the problems companies face and some of the ways they can adapt, including through new technology, revised approaches to launching new products and better relations with stakeholders.

Market Access Pricing Strategies Scrip 100

EU Regulatory Review – What Pharma Should Remember From 2017

You could be forgiven for thinking that Brexit was the only story in town on the European regulatory front in 2017, but there were of course plenty of other important developments during the year.

Policy Regulation Scrip 100

Dragon Tamer: New Models Needed To Capture China Opportunities

As China enacts reforms to open up to novel drugs, companies must rapidly change their approaches and adopt new business models to seize the window of opportunity, industry insiders tell a recent partnering event in the country.

China Research and Development Strategies Policy & Regulation
Advertisement
UsernamePublicRestriction

Register

Advertisement